HitGen Inc. announced that it has entered into a drug discovery research collaboration with Kymera Therapeutics Inc., to identify small molecule leads against targets of interest to Kymera. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to Kymera.

Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Kymera.